Evidence map›Paper›PMID 29681772›Full record

ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology

Thymic tumors and results of radiotherapy.

Sureyya Sarıhan, Ahmet Sami Bayram, Cengiz Gebitekin, Omer Yerci, Deniz Sıgırlı

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sureyya SarıhanDepartment of Radiation Oncology, Uludag University, Faculty of Medicine, Bursa, Turkey.
Ahmet Sami BayramDepartment of Thoracic Surgery, Uludag University, Faculty of Medicine, Bursa, Turkey.
Cengiz GebitekinDepartment of Thoracic Surgery, Uludag University, Faculty of Medicine, Bursa, Turkey.
Omer YerciDepartment of Pathology, Uludag University, Faculty of Medicine, Bursa, Turkey.
Deniz SıgırlıDepartment of Biostatistics, Uludag University, Faculty of Medicine, Bursa, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe aim of this study was to evaluate thymic epithelial tumors (TETs) for treatment outcomes and prognostic factors on survival.

backgroundTETs are very rare neoplasms and multidisciplinary approach is recommended according to prognostic factors. MATERIALS AND

methodsBetween 1995 and 2013, 31 patients were treated with median 5400 cGy (range: 1620-6596 cGy) radiotherapy (RT). Eleven patients received adjuvant or concurrent chemotherapy. There were 25 thymomas, 4 thymic carcinomas and 2 thymic neuroendocrin carcinomas. According to Masaoka, staging and WHO classification, cases were divided to good (

resultsIn January 2016, 22 cases were alive with median 51.5 months (range: 2-170.5) follow-up. Recurrences were observed in 29% of patients in median 29.5 months (range: 6.5-105). Local control, mean overall (OS) and disease-free survival (DFS) rates were 86%, 119 and 116 months, respectively. There was a significant difference for R0 vs. R+ resection (81% vs. 43%,

conclusionIn our study, prognostic risk stratification was shown to be a significant predictor of survival. There is a need to investigate subgroups that may or may not benefit from adjuvant RT.

Indexed as

3D-CRT/IMRT, three-dimensional conformal RT/intensity modulated RT4D-CT, four-dimensional computed tomographyCHE, chemotherapycm, centimeterCT, computed tomographyDFS, disease-free survivalLC, local controlMG, Myasthenia GravisNEC, thymic neuroendocrin carcinomaOS, overall survivalPET/CT, positron emission tomographyPF, prognostic factorR0, complete resectionR1, microscopic residual diseaseR2, macroscopic residual diseaseR+, incomplete resectionRT, radiotherapyTC, thymic carcinomaTET, thymic epitelial tumorWHO, World Health Organization

Identifiers

PMID29681772
PMCPMC5908383

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.